Company Profile

MBC Pharma Inc (AKA: MBC Research Inc)
Profile last edited on: 1/14/22      CAGE: 46Q92      UEI: GACCLMYMW3L3

Business Identifier: Therapies for metastatic bone disease and bone cancer.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

12635 East Montview Boulevard Suite 100
Aurora, CO 80045
   (720) 859-4040
Location: Single
Congr. District: 06
County: Adams

Public Profile

Also doing business and receiving awards as MBC Research Inc, MBC Pharma is a privately-held pre-clinical stage company engaged in new therapies for metastatic bone disease and bone cancer. The firm has recently demonstratedfirst human proof of concept efficacy in patients with breast or prostate cancer induced bone lesions. MBC Pharma’s patented technology is built on exploiting bone seeking properties of a well-known class of antiresorptive agents called bisphosphonates, which are used to deliver chemotherapeutic payloads directly to the cancer-induced sites of bone destruction. This is achieved by chemically linking bisphosphonate to chemotherapeutics in such a way that the compound can leave circulation intact and release both drugs (bisphosphonate and chemotherapeutic) in the bone microenvironment. Such anticancer bone-targeting conjugates will localize at the site of tumor cell induced bone destruction, providing a unique combination of antiresorptive and anticancer properties and resulting in increased local concentrations of cytotoxic agents. The aim is to greatly improve efficacy without increasing systemic toxicity of the chemotherapeutic

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2018 2 NIH $2,437,204
Project Title: Novel Bone-Targeting Combination Therapy for Osteosarcoma
2018 2 NIH $594,202
Project Title: Bone Targeted Antibiotics
2014 1 NIH $342,469
Project Title: Novel Vitamin B6 Based Prodrugs of Gemcitabine
2013 2 NIH $1,972,929
Project Title: Novel bisphosphonates for prostate cancer therapy
2009 2 NIH $858,509
Project Title: Novel Bisphosphonates for Multiple Myeloma Therapy

Key People / Management

  Alexander Karpeisky -- President, Chief Scientific Officer

  Shawn Patrick Zinnen -- CEO

  Monica M Reinholz

  David P Sebesta -- Chief Executive Officer

  Jean D Sibonga

  H Lee Sturgeon -- Former President